Ignacio Asial

CEO & Founder at DotBi at DotBio Pte. Ltd.

Presenter

DotBio is an emerging biotech company based in Singapore and San Francisco, focused on the rapid development of next-generation antibody therapeutics for diseases with significant unmet need. DotBio’s platform integrates advances in computational biology and molecular engineering to efficiently generate high-quality antibodies against challenging targets, including both extracellular and intracellular targets involved in cancer and autoimmune disorders.